Stifel Nicolaus Lowers ALX Oncology (NASDAQ:ALXO) Price Target to $1.50

ALX Oncology (NASDAQ:ALXO - Free Report) had its price target lowered by Stifel Nicolaus from $3.00 to $1.50 in a research note issued to investors on Friday, MarketBeat.com reports. The brokerage currently has a hold rating on the stock.

A number of other analysts have also recently commented on the stock. HC Wainwright reaffirmed a "buy" rating and set a $5.00 target price on shares of ALX Oncology in a report on Friday. Cantor Fitzgerald restated an "overweight" rating on shares of ALX Oncology in a research note on Friday, January 24th. Piper Sandler lifted their target price on ALX Oncology from $8.00 to $9.00 and gave the company an "overweight" rating in a research report on Thursday, March 6th. UBS Group reduced their price target on ALX Oncology from $4.00 to $2.20 and set a "buy" rating for the company in a research report on Monday, January 27th. Finally, Jefferies Financial Group upgraded ALX Oncology from a "hold" rating to a "buy" rating and boosted their price objective for the company from $2.00 to $3.00 in a research note on Thursday, March 6th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, ALX Oncology presently has an average rating of "Moderate Buy" and an average target price of $4.14.

ALX Oncology Stock Performance

Shares of NASDAQ ALXO traded up $0.08 during midday trading on Friday, hitting $0.97. 870,119 shares of the company's stock traded hands, compared to its average volume of 979,841. The firm has a fifty day moving average of $1.36 and a 200 day moving average of $1.58. ALX Oncology has a 1 year low of $0.89 and a 1 year high of $17.83. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.82 and a current ratio of 4.82. The stock has a market capitalization of $51.34 million, a price-to-earnings ratio of -0.33 and a beta of 1.01.

Remove Ads

Hedge Funds Weigh In On ALX Oncology

Several institutional investors have recently bought and sold shares of the stock. JSF Financial LLC bought a new position in shares of ALX Oncology during the 4th quarter valued at about $29,000. GSA Capital Partners LLP purchased a new stake in shares of ALX Oncology in the third quarter worth about $88,000. Sei Investments Co. bought a new position in ALX Oncology during the fourth quarter valued at approximately $102,000. Barclays PLC grew its holdings in ALX Oncology by 243.6% during the 3rd quarter. Barclays PLC now owns 59,502 shares of the company's stock valued at $107,000 after buying an additional 42,185 shares in the last quarter. Finally, Bridgeway Capital Management LLC purchased a new position in ALX Oncology during the 4th quarter valued at approximately $125,000. 97.97% of the stock is owned by hedge funds and other institutional investors.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.